Skip to main content
Publications
Morris MJ, de Bono J, Nagarajah J, Sartor O, Wei XX, Nordquist LT, Koshkin VS, Chi KN, Krause BJ, Herrmann K, Rahbar K, Vickers A Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: analysis of the phase 3 VISION trial
Craig T, Baptist A, Anderson J, Zaragoza-Urdaz R, Burnette A, Kelbel T, Riedl M, Vanegas A Boyle K Patient-reported outcomes among patients with hereditary angioedema within underrepresented racial or ethnic groups
Dolin P, Kielar D, Shavit A, Koegh K, Rowell J, Edmonds C, Meyers J Esterberg E Nham T Comorbidities in patients with eosinophilic granulomatosis with polyangiitis versus severe uncontrolled asthma: a retrospective analysis of US health insurance claims data
Dolin P, Kielar D, Shavit A, Keogh K, Rowell J, Edmonds C, Meyers J Esterberg L Nham T Healthcare resource utilization and costs in patients with eosinophilic granulomatosis with polyangiitis versus severe uncontrolled asthma: a retrospective analysis of US health insurance claims data
Thomas A, Danon L, Christensen H, Northstone K, Smith D, Nixon E, Trickey A, Hemani G, Sauchelli S Limits of lockdown: characterising essential contacts during physical distancing
Burte E, Leynaert B, Marcon A, Bousquet J, Benmerad M, Bono R, Carsin AE Long-term air pollution exposure is associated with increased severity of rhinitis in 2 European cohorts 10.1016/j.jaci.2019.11.040
Guerra S, Melen E, Sunyer J, Xu CJ, Lavi I, Benet M, Bustamante M, Carsin AE Genetic and epigenetic regulation of YKL-40 in childhood 10.1016/j.jaci.2017.06.030
Iribarren C, Rahmaoui A, Long AA, Szefler SJ, Bradley MS, Carrigan G, Eisner MD, Chen H, Omachi TA, Farkouh ME, Rothman KJ Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study of moderate-to-severe asthma 10.1016/j.jaci.2016.07.038.
White MV, Silvia S, Hollis K Goss D Odom D Bartsch J EPIPEN4SCHOOLS® survey combined analysis: prevalence and triggers of anaphylactic events
Hunter JE, Zepp JM, Gilmore MJ, Davis JV, Esterberg EJ Universal tumor screening for Lynch syndrome: assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers 10.1002/cncr.29470
Wooddell M, Goss DS Hollis KA Epinephrine administration for cases of anaphylaxis in a US school setting: results from the EpiPen4Schools survey
Gascon M, Casas M, Morales E, Valvi D, Ballesteros-Gomez A, Luque N, Rubio S, Monfort N, Ventura R, Martinez D Prenatal exposure to bisphenol A and phthalates and childhood respiratory tract infections and allergy 10.1016/j.jaci.2014.09.030
White MV, Goss D Hollis K EpiPen4Schools® survey: characteristics of anaphylaxis and common triggers
Hogue SL, Bennett ME, Goss DS Hollis KA Occurrence of anaphylaxis by school grade level and staff training: findings from the EpiPen4Schools survey
White MV, Goss DS Hollis KA EpiPen4Schools survey: characteristics of anaphylaxis and common triggers
Burris HA, Lebrun F, Rugo HS, Beck T, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial
Maurel J, Martins AS, Poveda A, Lopez-Guerrero JA, Cubedo R, Casado A, Martinez-Trufero J, Ramon Ayuso J, Lopez-Pousa A, Garcia-Albeniz X Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas 10.1002/cncr.25111
Sunyer J, Jarvis D, Pekkanen J, Chinn S, Janson C, Leynaert B, Luczynska C, Garcia-Esteban R Geographic variations in the effect of atopy on asthma in the European Community Respiratory Health Study 10.1016/j.jaci.2004.05.072
Kavuru M, Melamed J, Gross G, Laforce C, House K, Prillaman B Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial 10.1067/mai.2000.105711.
